| Title: |
Efficacy of JAK-JANUS Kinase Inhibitors as Mono Therapy and in Combination with Methotrexate in Active Rheumatoid Arthritis. |
| Authors: |
Wajid, Hamna; Rehman, Fawad; Rana, Zahid Hussain; Azam, Rizwan; Batool, Sidra; Hashmi, Zoha |
| Source: |
Pakistan Armed Forces Medical Journal; 2024 Supplement 2, Vol. 74, pS242-S242, 1p |
| Subject Terms: |
RHEUMATOID arthritis; MILITARY hospitals; KINASE inhibitors; METHOTREXATE; EXPERIMENTAL design |
| Abstract: |
Objective: To compare the efficacyof Janus kinase inhibitors as mono therapy and in combination with methotrexate in patients with active rheumatoid arthritis. Study Design: Quasi-experimental study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Hospital Multan, Pakistan, from Nov 2022 to Oct 2023. Methodology: A total of 1194 patients aging 18 years or above with active rheumatoid arthritis and taking Tofacitinab (5 mg twice daily) were included in this study. In Group-A patients were continued with oral Tofacitinab (5 mg twice daily) while patients in Group-B were added oral methotrexate (15-25 mg per week). The study's primary outcome was set as the number of patients achieving ACR50 at 6 months of the treatment. Secondary outcomes were the patients achieving ACR70, low disease activity (SDAI 511), remission (SDAI 53.3) and response of ≥0.22 in HAQ-D index at 6 months follow up. Results: The Mean±SD of age in this study was 51.66±9.36 years. The female gender was 72.61% of total population while males were 27.39%. The results of the primary outcomes of the study show a statistically significant difference between Group-A and Group-B (39.20% Vs 44.72 respectively, p=0.05) proving the combination therapy to be more effective than monotherapy. Among secondary end points, significantly more patients achieved ACR 70 rate, SDAI 511 and SDAI 53.3 in Group-B compared to Group-A, however, no statistically significant difference was present regarding achieving ≥0.22 response at HAQ-D index. Conclusion: The combination of a JAK inhibitor with methotrexate is more effective in the treatment of patients with active rheumatoid arthritis compared to JAK inhibitor monotherapy. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Pakistan Armed Forces Medical Journal is the property of Knowledge Bylanes and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |